Emerging drugs for epilepsy

• SANDER JWAS, SHORVON SD: Epidemiology of the epilepsies. J. Neurol. Neurosurg. Psychiatry (1996) 61:433-443.
   PubMed Web of Science ®Google Scholar
• HAUSER WA, ANNEGERS JF, ROCCA WA: Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin. Proc. (1996) 71:576-586.
   PubMed Web of Science ®Google Scholar
• KWAN P, BRODIE MJ: Early identification of refractory epilepsy. N. Engl. J. Med. (2000) 342:314-319.
   PubMed Web of Science ®Google Scholar
• KWAN P, SANDER JW: The natural history of epilepsy: an epidemiological view. J. Neurol. Neurosurg. Psychiatry (2004) 75:1376-1381.
   PubMed Web of Science ®Google Scholar
• FISHER RS, VAN EMDE BOAS W, BLUME W et al.: Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia (2005) 46:470-472.
   PubMed Web of Science ®Google Scholar
• COMMISSION ON CLASSIFICATION AND TERMINOLOGY OF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia (1981) 22:489-501.
   PubMed Web of Science ®Google Scholar
• COMMISSION ON CLASSIFICATION AND TERMINOLOGYOF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY: Proposal for revised clinical classification of epilepsies and epileptic syndromes. Epilepsia (1989) 30:389-399.
   PubMed Web of Science ®Google Scholar
• MCCORMICK DA, CONTRERAS D: On the cellular and network bases of epileptic seizures. Ann. Rev. Physiol. (2001) 63:815-846.
   PubMed Web of Science ®Google Scholar
• ROGAWSKI MA, LÖSCHER W: The neurobiology of antiepileptic drugs. Nat. Rev. (2004) 5:553-564.
   Google Scholar
• MULLEY JC, SCHEFFER IE, PETROU S, BERKOVIC SF: Channelopathies as a genetic cause of epilepsy. Curr. Opin. Neurol. (2003) 16:171-176.
   PubMed Web of Science ®Google Scholar
• TOMSON T, BEGHI E, SUNDQVIST A, JOHANNESSEN SI: Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Res. (2004) 60:1-16.
   PubMed Web of Science ®Google Scholar
• LAWN ND, BAMLET WR, RADHAKRISHNAN K, O'BRIEN PC, SO EL: Injuries due to seizures in persons with epilepsy: a population-based study. Neurology (2004) 63:1565-1570.
   PubMed Web of Science ®Google Scholar
• GAITATZIS A, JOHNSON AL, CHADWICK DW, SHORVON SD, SANDER JW: Life expectancy in people with newly diagnosed epilepsy. Brain (2004) 127:2427-2432.
   PubMed Web of Science ®Google Scholar
• MOHANRAJ R, NORRIE J, STEPHEN LJ et al.: Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol. (2006) 5:481-487.
   PubMed Web of Science ®Google Scholar
• BAZIL CWL: Comprehensive care of the epilepsy patient – control, comorbidity, and cost. Epilepsia (2004) 45(Suppl. 6):3-12.
   PubMedGoogle Scholar
• SCHACHTER SC: Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors. Expert Rev. Neurother. (2006) 6:111-118.
   PubMed Web of Science ®Google Scholar
• BEGLEY CE, FAMULARI M, ANNERGERS JF et al.: The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia (2000) 41:342-351.
   PubMed Web of Science ®Google Scholar
• KWAN P, BRODIE MJ: Combination therapy in epilepsy: when and what to use? Drugs (2006) 66:1817-1829.
   PubMed Web of Science ®Google Scholar
• FRENCH JA, KANNER AM, BAUTISTA J et al.: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology (2004a) 62:1252-1260.
   PubMed Web of Science ®Google Scholar
• MARSON AG, WILLIAMSON PR, HUTTON JL, CLOUGH HE, CHADWICK DW: Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia (2002) 43:505-513.
   PubMed Web of Science ®Google Scholar
• KWAN P, BRODIE MJ: Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia (2004) 45:1141-1149.
   PubMed Web of Science ®Google Scholar
• KWAN P, BRODIE MJ: Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology (2003) 60(Suppl. 4):S2-S12.
   PubMedGoogle Scholar
• BRODIE MJ, PERUCCA E, RYVLIN P, BEN-MENACHEM E, MEENCKE H-J; FOR THE LEVETIRACETAM MONOTHERAPY STUDY GROUP: Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology (2007) 68:402-408.
   PubMed Web of Science ®Google Scholar
• GLAUSER T, BEN-MENACHEM E, BOURGEOIS B et al.: ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2006) 47:1094-1120.
   PubMed Web of Science ®Google Scholar
• MARSON AG, AL-KHARUSI A, ALWAIDH M et al.: The SANAD study of effectiveness of valproate, lamotrigine and topiramate for generalised and unclassified epilepsy: an unblinded randomised controlled trial. Lancet (2007) 369:1016-1026.
   PubMed Web of Science ®Google Scholar
• MARSON AG, AL-KHARUSI AM, ALWAIDH M et al.: The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet (2007) 369:1000-1015.
   PubMed Web of Science ®Google Scholar
• MOHANRAJ R, BRODIE MJ: Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur. J. Neurol. (2006) 13:277-282.
   PubMed Web of Science ®Google Scholar
• MOHANRAJ R, BRODIE MJ: Measuring the efficacy of antiepileptic drugs. Seizure (2003) 12:413-443.
   PubMed Web of Science ®Google Scholar
• FRENCH JA, KANNER AM, BAUTISTA J et al.: Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology (2004b) 62:1261-1273.
   PubMed Web of Science ®Google Scholar
• ARROYO S, DE LA MORENA A: Life-threatening adverse events of antiepileptic drugs. Epilepsy Res. (2001) 47:155-174.
   PubMed Web of Science ®Google Scholar
• WYSZYNSKI DF, NAMBISAN M, SURVE T, ALSDORF RM, SMITH CR, HOLMES LB; FOR THE ANTIEPILEPTIC DRUG PREGNANCY REGISTRY: increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology (2005) 64:961-965.
   PubMed Web of Science ®Google Scholar
• ARTAMA M, AUVINEN A, RAUDASKOSKI T, ISOJARVI I, ISOJARVI J: Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology (2005) 64:1874-1878.
   PubMed Web of Science ®Google Scholar
• MORROW J, RUSSELL A, GUTHRIE E et al.: Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry (2006) 77:193-198.
   PubMed Web of Science ®Google Scholar
• MEADOR KJ, BAKER GA, FINNELL RH et al.: In utero antiepileptic drug exposure: fetal death and malformations. Neurology (2006) 67:407-412.
   PubMed Web of Science ®Google Scholar
• TIAN G-F, AZMI H, TAKANO T et al.: Astrocytic basis of epilepsy. Nat. Med. (2005) 11:973-981.
   PubMed Web of Science ®Google Scholar
• KWAN P, SILLS GJ, BRODIE MJ: The mechanisms of action of commonly used antiepileptic drugs. Pharmacol. Ther. (2001) 90:21-34.
   PubMed Web of Science ®Google Scholar
• LYNCH BA, LAMBENG N, NOCKA K et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA (2004) 101:9861-9866.
   PubMed Web of Science ®Google Scholar
• LÖSCHER W, SCHMIDT D: Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. (1988) 2:145-181.
   PubMed Web of Science ®Google Scholar
• STABLES JP, BERTRAM E, DUDEK FE et al.: Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia (2003) 44:1472-1478.
   PubMedGoogle Scholar
• SMITH M, WILCOX KS, WHITE HS: Discovery of antiepileptic drugs. Neurotherapeutics (2007) 4:12-17.
   PubMed Web of Science ®Google Scholar
• WHITE HS: Comparative anticonvulsant and mechanistic profile of established and newer antiepileptic drugs. Epilepsia (1999) 40(Suppl. 5):S2-S10.
   PubMed Web of Science ®Google Scholar
• LÖSCHER W, HONACK D: Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. (1993) 232:147-158.
   PubMed Web of Science ®Google Scholar
• ROGAWSKI MA: Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. (2006) 69:273-294.
   PubMed Web of Science ®Google Scholar
• POLLARD JR, FRENCH J: Antiepileptic drugs in development. Lancet Neurol. (2006) 5:1064-1067.
   PubMed Web of Science ®Google Scholar
• KENDA BM, MATAGNE AC, TALAGA PE et al.: Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J. Med. Chem. (2004) 47:530-549.
   PubMed Web of Science ®Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, PERUCCA E, TOMSON T: Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. (2004) 61:1-48.
   PubMed Web of Science ®Google Scholar
• VON ROSENSTEIL P: Brivaracetam (UCB24714). Neurotherapeutics (2007) 4:84-87.
   PubMed Web of Science ®Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, PERUCCA E, TOMSON T: Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res. (2007) 73:1-52.
   PubMed Web of Science ®Google Scholar
• KASTELEIJN-NOLST TRENITÈDGA, PARAIN D, MASNOU P, GENTON P, STEINHOFF BJ, HIRSCH E: Proof of principle in the new AED ucb 34714; use of the photosensitivity model. Epilepsia (2004) 45(Suppl. 7):309.
   PubMed Web of Science ®Google Scholar
• KASTELEIJN-NOLST TRENITÈ D, ABOU-KHALIL B, FRENCH J et al.: Proof of principle in the new antiepileptic drug seletracetam (ucb 44212) in the photosensitivity model. Presented in 1st North American Epilepsy Congress, San Diego, CA. (1 – 5 December 2006).
   Google Scholar
• BONIFACIO MJ, SHERIDAN RD, PARADA A, CUNHA RA, PATMORE L, SOARES-DA-SILVA P: Interaction of the novel anticonvulsant, BIA2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia (2001) 42:600-608.
   PubMed Web of Science ®Google Scholar
• WUTTKE TV, LERCHE H: Novel anticonvulsant drugs targeting voltage-dependent ion channels. Expert Opin. Investig. Drugs (2006) 15:1167-1177.
   PubMed Web of Science ®Google Scholar
• ELGER C, BIALER M, CRAMER JA, MAIA J, ALMEIDA L, SOARES-DA-SILVA P: Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia (2007) 48:497-504.
   PubMed Web of Science ®Google Scholar
• ALMEIDA L, SOARES-DA-SILVA P: Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics (2007) 4:88-96.
   PubMed Web of Science ®Google Scholar
• POPOVIC M, NIERKENS S, PIETERS R, UETRECHT J: Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions. Chem. Res. Toxicol. (2004) 17:1568-1576.
   PubMed Web of Science ®Google Scholar
• ROECKLEIN BU, SACKS HJ, MORTKO H, STABLES J: Fluorofelbamate. Neurotherapeutics (2007) 4:97-101.
   PubMed Web of Science ®Google Scholar
• WHITE HS, SRIVASTAVA A, KLEIN B et al.: The novel investigational neuromodulator RWJ 333369 displays a broad-spectrum anticonvulsant profile in rodent seizure and epilepsy models. Presented in 1st North American Epilepsy Congress, San Diego, CA (1 – 5 December 2006).
   Google Scholar
• TRENITE DG, FRENCH JA, HIRSCH E et al.: Evaluation of carisbamate, a novel antiepileptic drug in photosensitive epilepsy: an exploratory, placebo-controlled study. Epilepsy Res. (In Press).
   Google Scholar
• NOVAK GP, KELLEY M, ZANNIKOS P, KLEIN B: Carisbamate (RWJ-333369). Neurotherapeutics (2007) 4:106-109.
   Google Scholar
• BIALER M, YAGEN B: Valproic acid: second generation. Neurotherapeutics (2007) 4:130-137.
   PubMed Web of Science ®Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E, TOMSON T: Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. (2002) 51:31-71.
   PubMed Web of Science ®Google Scholar
• RUNDFELDT C, NETZER R: The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. (2000) 282:73-76.
   PubMed Web of Science ®Google Scholar
• ROGAWSKI MA: KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. (2000) 23:393-398.
   PubMed Web of Science ®Google Scholar
• BIEVERT C, SCHROEDER BC, KUBISCH C et al.: A potassium channel mutation in neonatal human epilepsy. Science (1998) 279:403-406.
   PubMed Web of Science ®Google Scholar
• SINGH NA, CHARLIER C, STAUFFER D et al.: A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet. (1998) 18:25-29.
   PubMed Web of Science ®Google Scholar
• CHARLIER C, SINGH NA, RYAN SG et al.: A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat. Genet. (1998) 18:53-55.
   PubMed Web of Science ®Google Scholar
• ROSTOCK A, TOBER C, RUNDFELDT C et al.: D-23129: a new anticonvulsant with a braod spectrum activity in animal models of epileptic seizures. Epilepsy Res. (1996) 23:211-223.
   PubMed Web of Science ®Google Scholar
• PORTER RJ, NOHRIA V, RUNDFELDT C: Retigabine. Neurotherapeutics (2007) 4:149-154.
   PubMed Web of Science ®Google Scholar
• PORTER RJ, PARTIOT A, SACHDEO R, NOHRIA V, ALVES WM; FOR THE 205 STUDY GROUP: Randomized, multicentre, dose-ranging trial of retigabine for partial-onset seizures. Neurology (2007) 68:1197-1204.
   PubMed Web of Science ®Google Scholar
• HOWES JF, BELL C: Talampanel. Neurotherapeutics (2007) 4:126-129.
   PubMed Web of Science ®Google Scholar
• SOLYOM S, TARNAWA I: Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr. Pharm. Des. (2002) 8:913-939.
   PubMed Web of Science ®Google Scholar
• CHAPPELL AS, SANDER JW, BRODIE MJ et al.: A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology (2002) 58:1680-1682.
   PubMed Web of Science ®Google Scholar
• FETELL MR, RAMSAY RE, BELL C, TANG S: Efficacy of the AMPA antagonist talampanel in refractory partial epilepsy J. Neurol. Sci. (2005) (Suppl. 1):A238 (Abstract).
   Google Scholar
• REDDY DS: Pharmacology of endogenous neuroactive steroids. Crit. Rev. Neurobiol. (2003) 15:197-234.
   PubMedGoogle Scholar
• REDDY DS, ROGAWSKI MA: Chronic treatment with neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol. Exp. Ther. (2000) 295:1241-1248.
   PubMed Web of Science ®Google Scholar
• NOHRIA V, GILLER E: Ganaxolone. Neurotherapy (2007) 4:102-105.
   PubMed Web of Science ®Google Scholar
• ERRINGTON AC, COYNE L, STÖHR T et al.: Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology (2006) 50:1016-1029.
   PubMed Web of Science ®Google Scholar
• THOMAS D, SCHARFENECKER U, SCHILTMEYER B, DOTY P, CAWELLO W, R HORSTMANN R: Low potential for drug–drug-interaction of lacosamide. Presented in 1st North American Epilepsy Congress, San Diego, CA (1 – 5 December 2006).
   Google Scholar
• HALASZ P, KALVIAINEN R, MAZURKIEWICZ-BELDZINSKA M, ROSENOW F, DOTY P, SULLIVAN T: Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures. Presented in 1st North American Epilepsy Congress, San Diego, CA (1 – 5 December 2006).
   Google Scholar
• BEN-MENACHEM E, BITON V, JATUZIS D, ABOU-KHALIL B, DOTY P, RUDD GD: Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia (In Press).
   Google Scholar
• KRAUSS G, BEN-MENACHEM E, MAMENISKIENE R, VAICIENE N, BROCK M, WHITESIDES J: Intravenous lacosamide (SPM 927) as replacement for oral lacosamide in subjects with partial seizures: a multicenter, open-label, inpatient safety and tolerability trial. Presented in 1st North American Epilepsy Congress, San Diego, CA (1 – 5 December 2006).
   Google Scholar
• ARROYO S: Rufinamide. Neurotherapeutics (2007) 4:155-162.
   PubMed Web of Science ®Google Scholar
• DEEKS ED, SCOTT LJ: Rufinamide. CNS Drugs (2006) 20:751-760.
   PubMed Web of Science ®Google Scholar
• ALDENKAMP AP, ALPHERTS WCJ: The effects of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia (2006) 47:1153-1159.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Rufinamide. GCP 33101, E 2080, RUF 331, Xilep. Drugs R. D. (2005) 6:249-252.
   PubMedGoogle Scholar
• CHENG-HAKIMIAN A, ANDERSON GD, MILLER JW: Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int. J. Clin. Pract. (2006) 60:1497-1501.
   PubMed Web of Science ®Google Scholar
• FARIELLO RG: Safinamide. Neurotherapeutics (2007) 4:110-116.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Safinamide. FCE 26743, NW 1015, PNU 151774, PNU 151774E. Drugs R. D. (2004) 5:355-358.
   Google Scholar
• QUILICHINI PP, CHIRON C, BEN-ARI Y, GOZLAN H: Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A-receptor channels. Epilepsia (2006) 47:706-716.
   Google Scholar
• CHIRON C, MARCHAND MC, TRAN A et al.: Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndromededicated trial. STICLO study group. Lancet (2000) 356:1638-1642.
   PubMed Web of Science ®Google Scholar
• CHIRON C: Stiripentol. Neurotherapeutics (2007) 4:123-125.
   PubMed Web of Science ®Google Scholar
• KWAN P, BRODIE MJ: Refractory epilepsy: mechanisms and solutions. Expert Rev. Neurother. (2006) 6:397-406.
   PubMedGoogle Scholar
• MELDRUM BS, ROGAWSKI MA: Molecular targets for antiepileptic drug development. Neurotherapeutics (2007) 4:18-61.
   PubMed Web of Science ®Google Scholar
• FISHER RS, HO J: Potential new methods for antiepileptic drug delivery. CNS Drugs (2002) 16:579-593.
   PubMed Web of Science ®Google Scholar
• LESCHZINER GD, ANDREW T, PIRMOHAMED M, JOHNSON MR: ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenom. J. (2007) 7:154-179.
   PubMed Web of Science ®Google Scholar
• KWAN P, BAUM L, WONG V et al.: Association between ABCB1 C3435T polymorphism and drug resistant epilepsy in Han Chinese. Epilepsy Behav. (In Press).
   Google Scholar
• CHUNG WH, HUNG SI, HONG HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature (2004) 428:486.
   PubMed Web of Science ®Google Scholar
• MAN CBL, KWAN P, BAUM L et al.: Association between HLA-B*1502 allele and antiepileptic drugs-induced cutaneous reactions in Han Chinese. Epilepsia (2007) 48:1015-1018.
   Google Scholar

Websites

• http//:www.nice.org.uk/CG020NICEguideline NICE: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. (Accessed 27 April 2007).
   Google Scholar
• http//www.clinicaltrials.gov/ct/show/NCT00150800?order=1 (Accessed 9 February 2007).
   Google Scholar